Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Co-developing with the Stevanato Group, Bexson introduces a platform providing users with control of their post-surgical pain management (BB106 ketamine) and delivery of other small molecules (licensed via the SeVALENT™ platform) in a safe, intuitive, and stress-free experience.
Explore Military Applications →
A Completely Enhanced Route of Drug Delivery
We are meeting our ambitious goal to develop a modular device leapfrogging prior industry innovations for subcutaneous or dose metered infusion.
Our wearable device is pre–filled and pre-sterilized with features that offer best-in-class tamper resistance and diversion control to mitigate potential misuse.
Bexson’s Device & SeVALENT™: The solution for pain management, mental health treatments and other small molecule delivery
Both steady state & bolus
Bolus only
Continuous Delivery. Both basal & bolus
Bolus only
Bolus only
Bolus only
In-clinic only
In-clinic only
In-clinic & at home
In-clinic & at home
In-clinic & at home
In-clinic & at home
Highest 100%
High 93%
High > 80%
Very Low
11-20%
Mod 25-50%
Low 30%
Low
Low
Low
Very High
High
High
High
Moderate
Low to Moderate
Low
Low to Moderate
Low to Moderate
Low
Low
Low
High
Moderate to High
Moderate to High
Both steady state & bolus
In-clinic only
Highest 100%
Low
High
Low
Bolus only
In-clinic only
High 93%
Low
Moderate
Low
Both steady state & bolus
In-clinic & at home
High > 80%
Low
Low to Moderate
Low
Bolus only
In-clinic & at home
Very Low 11-20%
Very High
Low
High
Bolus only
In-clinic & at home
Mod 25-50%
High
Low to Moderate
Moderate to High
Bolus only
In-clinic & at home
Low 30%
High
Low to Moderate
Moderate to High
Bexson has partnered with the Stevanato Group, one of the world’s leading drug containment, drug delivery, and component development & manufacturing companies.
Read the Latest Article
Infectious Endocarditis is a serious, life-threatening bacterial infection of heart tissue that is a common problem in intravenous (IV) drug delivery, due to the introduction of skin flora to the blood circulation. These patients usually need potent, long-term antibiotic treatments that can only be achieved through daily IV infusions – requiring hospitalization, daily clinic visits, and/or home health services.
The unique Bexson/Stevanato Group product line can resolve the need for IV delivery, increase safety and convenience, and vastly reduce the cost of care and procedural burden. Rather than an extended hospital stay or daily travel to the clinic, patients would be able to place the patch pump themselves and deliver the therapy at home without IV catheters, saline bags, and unwieldy poles and IV pumps.
Many drugs would cause tissue irritation if delivered subcutaneously due to non compatible solution pH and osmolality. These factors can cause sterile abscess. In addition, large volumes also create issues with this route of administration.
However, Bexson’s 7-Valence Salt formulation normalizes hundreds of drug APIs to a near exact match of the pH and osmolality of subcutaneous tissue and permits solution concentration (on average approximately 10:1) to allow wearable technology.
This remarkable advancement paired with the new delivery platform represent a massive opportunity to resolve the inconvenience and cost of the IV drug delivery market ($350 billion in size by 2030)
The two-part design allows the drive unit to be separated from the drug pod for reuse, while having the capacity to produce pre-filled and pre-sterilized drug pods. This is also a key feature of the tamper resistance and diversion control strategy because it forbids the possibility of running more than one pod at a time.
The joint Bexson and Stevanato Group strategy has been to design an innovative device that can be repurposed effectively for many different applications. The device is highly modular and will accommodate many other small-molecule formulations.
At the same time, Bexson Biomedical is tailoring SeVALENT™ formulations with therapeutic dosing potential ranging from 1-hour to 3-days using the standard and modular 3 mL cartridge.
The companies’ respective technologies complement each other. Having a partner that can manage an entire project – from container closure system to assembly technology, up to mass production – is key to bringing a device to market faster and more easily.
Read Article
The combination of AKESO and BB106 is designed to provide non-opioid pain management on the battlefield.
Explore Military Applications
